DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Stock Performance

DRRX stock opened at $0.93 on Friday. The firm has a market cap of $28.83 million, a P/E ratio of -1.52 and a beta of 1.01. The firm’s fifty day moving average is $1.10 and its 200 day moving average is $1.31. DURECT has a 52 week low of $0.51 and a 52 week high of $1.88.

Institutional Investors Weigh In On DURECT

Several institutional investors have recently added to or reduced their stakes in DRRX. Richmond Brothers Inc. boosted its holdings in shares of DURECT by 39.5% during the second quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after purchasing an additional 303,670 shares during the period. Geode Capital Management LLC grew its position in shares of DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 14,658 shares during the last quarter. Finally, International Assets Investment Management LLC increased its stake in shares of DURECT by 41.3% during the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after buying an additional 6,300 shares during the period. Hedge funds and other institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.